Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.56 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | CBFB | Q13951 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 6/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049957 | 0.87 | AURKA (0.44) | SCDAURKABRAFCBFBTRPV1 | |
| SCHEMBL4058430 | 0.86 | AURKA (0.61) | SCDAURKAIKBKETBK1AURKB | |
| SCHEMBL4059384 | 0.86 | AURKA (0.55) | AURKATRPV1IKBKETBK1AURKB | |
| SCHEMBL4051509 | 0.84 | SCD (0.63) | SCDAURKACYP3A4TRPA1FADS1 | |
| SCHEMBL4052831 | 0.82 | SCD (0.58) | SCDAURKACYP3A4TRPA1FADS1 | |
| SCHEMBL13607901 | 0.82 | SCD (0.44) | SCDCBFBTRPV1FADS1CDK2 | |
| SCHEMBL4053465 | 0.79 | IKBKE (0.49) | AURKABRAFTRPV1IKBKETBK1 | |
| SCHEMBL4053038 | 0.79 | AURKA (0.49) | AURKATRPV1CYP3A4IKBKETBK1 | |
| SCHEMBL4226507 | 0.79 | SCD (0.48) | SCDAURKABRAFCYP3A4TRPA1 | |
| SCHEMBL4057667 | 0.79 | AURKA (0.60) | AURKABRAFTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | SCD 4559/4885AURKA 247/4885BRAF 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.